Effects of muramyl peptides on macrophages, monokines, and sleep

被引:40
作者
Pabst, MJ
Beranova-Giorgianni, S
Krueger, JM
机构
[1] Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA
[2] Univ Tennessee, Dept Oral Biol, Memphis, TN 38163 USA
[3] Washington State Univ, Dept Vet & Comparat Anat Pharmacol & Physiol, Pullman, WA 99164 USA
关键词
muramyl peptides; peptidoglycan; macrophages; oxygen radicals; superoxide; interleukin-1; tumor necrosis factor-alpha; fever; sleep;
D O I
10.1159/000026384
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Muramyl peptides are fragments of peptidoglycan from the cell walls of bacteria. Because of their unique chemistry, the immune system recognizes that muramyl peptides are products of bacteria, and it responds by becoming activated to resist infection. This resistance to infection is nonspecific, and extends to unrelated species of bacteria, fungi, and viruses. A key mechanism of the resistance to infection is activation of macrophages. Macrophage activation results in increased production of microbicidal oxygen radicals like superoxide and peroxide, and in increased secretion of inflammatory cytokines like interleukin-1 beta and tumor necrosis factor-alpha. These cytokines, besides activating neutrophils, B lymphocytes, and T lymphocytes, act on the central nervous system to induce physiological responses like fever and sleep. These physiological responses also aid in combating infection. Muramyl peptides also activate macrophages and other cells of the immune system to kill cancer cells. Muramyl peptides and similar agents will become more important as therapeutic agents in the future, due to increasing resistance of microbes to antibiotics, and increasing numbers of patients with immunodeficiencies.
引用
收藏
页码:261 / 283
页数:23
相关论文
共 173 条
[41]   Microglia digest Staphylococcus aureus into low molecular weight biologically active compounds [J].
Fincher, EF ;
Johannsen, L ;
Kapas, L ;
Takahashi, S ;
Krueger, JM .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 1996, 271 (01) :R149-R156
[42]   Neutrophils, but not monocytes or microglia, degraded interleukin-1 beta in vitro [J].
Fincher, EF ;
Pabst, MJ ;
Krueger, JM .
NEUROIMMUNOMODULATION, 1996, 3 (2-3) :82-86
[43]  
FINKEL TH, 1987, J BIOL CHEM, V262, P12589
[44]   LIPOPOLYSACCHARIDE PRIMING OF HUMAN-NEUTROPHILS FOR AN ENHANCED RESPIRATORY BURST - ROLE OF INTRACELLULAR FREE CALCIUM [J].
FOREHAND, JR ;
PABST, MJ ;
PHILLIPS, WA ;
JOHNSTON, RB .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (01) :74-83
[45]   RAPID ELIMINATION OF A SYNTHETIC ADJUVANT PEPTIDE FROM THE CIRCULATION AFTER SYSTEMIC ADMINISTRATION AND ABSENCE OF DETECTABLE NATURAL MURAMYL PEPTIDES IN NORMAL SERUM AT CURRENT ANALYTICAL LIMITS [J].
FOX, A ;
FOX, K .
INFECTION AND IMMUNITY, 1991, 59 (03) :1202-1205
[46]   LIPOSOME-ENCAPSULATED MURAMYL TRIPEPTIDE PHOSPHATIDYLETHANOLAMINE FOR THE TREATMENT OF FELINE MAMMARY ADENOCARCINOMA - A MULTICENTER RANDOMIZED DOUBLE-BLIND-STUDY [J].
FOX, LE ;
MACEWEN, EG ;
KURZMAN, ID ;
DUBIELZIG, RR ;
HELFAND, SC ;
VAIL, DM ;
KISSEBERTH, W ;
LONDON, C ;
MADEWELL, BR ;
RODRIGUEZ, CO ;
JEGLUM, KA ;
ROSENBERG, M ;
ROSENTHAL, RC .
CANCER BIOTHERAPY, 1995, 10 (02) :125-130
[47]   MTP-PE IN LIPOSOMES AS A BIOLOGICAL RESPONSE MODIFIER IN THE TREATMENT OF CANCER - CURRENT STATUS [J].
FROST, H .
BIOTHERAPY, 1992, 4 (03) :199-204
[48]   CYTOKINE PRODUCTION AND IMMUNE CELL ACTIVATION IN MELANOMA PATIENTS TREATED WITH LIPOSOMAL MURAMYL TRIPEPTIDE (CGP-19835A LIPID) [J].
FUJIMAKI, W ;
ITOH, K ;
AN, T ;
GANO, JB ;
ROSS, MI ;
MANSFIELD, PF ;
BALCH, CM ;
AUGUSTUS, LB ;
KARKEVITCH, DD ;
JOHNSTON, D ;
FIDLER, IJ ;
KLEINERMAN, ES .
CANCER BIOTHERAPY, 1993, 8 (04) :307-318
[49]   EFFECT OF IBUPROFEN ON MONOCYTE ACTIVATION BY LIPOSOME-ENCAPSULATED MURAMYL TRIPEPTIDE PHOSPHATIDYLETHANOLAMINE (CGP-19835A) - CAN IBUPROFEN REDUCE FEVER AND CHILLS WITHOUT COMPROMISING IMMUNE STIMULATION [J].
FUJIMAKI, W ;
GRIFFIN, JR ;
KLEINERMAN, ES .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1993, 36 (01) :45-51
[50]  
FUKUOKA M, 1989, ARZNEIMITTEL-FORSCH, V39-1, P90